Presidio Medical

Executive Summary

Presidio Medical is a neuromodulation company focused on transforming the treatment of chronic nociceptive pain by balancing the human nervous system. Unlike traditional neuromodulation devices that may offer limited relief or require frequent adjustments, Presidio's proprietary technology aims to break the cycle of constrained thinking about pain management. The company's approach leverages novel waveforms and targeted stimulation to modulate pain signals at the source, potentially offering a more durable and effective solution for patients who have failed conventional therapies. With a strong foundational platform designed in Sunnyvale, California, Presidio seeks to address the large underserved market of chronic pain sufferers, estimated to affect over 50 million adults in the United States alone. Currently operating in the pre-clinical stage, Presidio Medical has not yet disclosed specific funding rounds or valuation, but its established presence since 1985 suggests a long-term commitment to the field. The company's profile indicates a focused strategy on neuromodulation and medical devices, with no commercial products to date. Near-term progress hinges on completing pre-clinical studies, securing intellectual property protection, and attracting strategic partnerships or investment to advance toward first-in-human trials. While the path to market remains lengthy, Presidio's differentiated approach and experienced foundation position it as a potential disruptor in chronic pain management.

Upcoming Catalysts (preview)

• Q3 2026Preclinical data readout at a major pain conference70% success
• Q4 2026Series A funding round to support IND-enabling studies50% success
• Q1 2027FDA pre-submission meeting for device classification guidance60% success